HC Wainwright Has Bullish Forecast for Precigen Q3 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Equities research analysts at HC Wainwright raised their Q3 2027 EPS estimates for shares of Precigen in a research note issued to investors on Thursday, May 28th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.10 per share for the quarter, up from their previous estimate of $0.09. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for Precigen’s FY2028 earnings at $0.72 EPS, FY2029 earnings at $1.14 EPS and FY2030 earnings at $1.44 EPS.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The business had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million.

PGEN has been the topic of several other reports. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Wall Street Zen lowered shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Tuesday, April 21st. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Finally, Citizens Jmp lifted their target price on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Precigen currently has a consensus rating of “Hold” and an average target price of $12.50.

Precigen Price Performance

Shares of Precigen stock opened at $4.34 on Monday. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The firm’s 50-day simple moving average is $4.02 and its 200-day simple moving average is $4.09. Precigen has a twelve month low of $1.28 and a twelve month high of $5.47. The firm has a market cap of $1.55 billion, a P/E ratio of -3.68 and a beta of 1.06.

Hedge Funds Weigh In On Precigen

Large investors have recently modified their holdings of the stock. State of Wyoming acquired a new position in shares of Precigen during the first quarter worth approximately $27,000. NBC Securities Inc. acquired a new position in shares of Precigen during the fourth quarter worth approximately $38,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Precigen during the third quarter worth approximately $39,000. Royal Bank of Canada lifted its position in shares of Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,426 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Precigen during the third quarter worth approximately $41,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Randal J. Kirk sold 4,772,781 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $3.30, for a total transaction of $15,750,177.30. Following the transaction, the director directly owned 302,213 shares in the company, valued at approximately $997,302.90. This represents a 94.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 47.10% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.